Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Fresh Tracks Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Fresh Tracks Therapeutics announced earnings per share of $-2.0700 on revenue of $486K. Analysts polled by Investing.com EPS of $-1.4300 on revenue of $206.67K.
Fresh Tracks Therapeutics 's are down 28.35% and is trading at $1.7700 , still down 90.66% from its 52 week high of $18.94 set on Tuesday, April 19, 2022.
Fresh Tracks Therapeutics follows other major Healthcare sector earnings this month
Fresh Tracks Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar